Amneal Pharmaceuticals Inc Class A (AMRX)
$17.44
$5.26
(43.19%)
As on 04-Sep-2026 16:00EDT
Market cap
$6,074 Mln
Revenue (TTM)
$3,118 Mln
P/E Ratio
36.3
P/B Ratio
186.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.6 %
-
ROCE
-- %
-
Industry P/E
37.91
-
EV/EBITDA
14.2
-
Debt to Equity
77.7
-
Book Value
$0.1
-
EPS
$0.5
-
Face value
--
-
Shares outstanding
348,296,027
10 Years Aggregate
CFO
$1,849.82 Mln
EBITDA
$3,215.23 Mln
Net Profit
$-301.93 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
| -- | -- | -- | 82.8 | 60.5 | 26.3 | -3.2 |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
17.4 | 6,074.3 | 3,117.6 | 157.4 | 14.7 | -- | 36.3 | 186.5 |
| 206.7 | 10,826.1 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 131.0 | |
| 74.8 | 14,974.8 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 111.6 | 12,310.3 | 830.8 | 54.9 | 3.2 | 8.1 | 264.8 | 17.9 | |
| 12.0 | 10,020.9 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 29.3 | 2.5 | |
| 24.5 | 12,236.5 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.9 | |
| 7.8 | 5,233.7 | 7,430.4 | 452.5 | 17.6 | 7 | 10 | 0.8 | |
| 285.6 | 5,591.7 | 290.5 | 197.2 | 82.5 | 19.9 | 28.9 | 5.9 | |
| 68.7 | 6,058.9 | 450.9 | 138.6 | 39.1 | 115.6 | 50.1 | 32.1 | |
| 124.7 | 8,865.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 21.5 |
Shareholding Pattern
View DetailsAbout Amneal Pharmaceuticals Inc Class A (AMRX)
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and... internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. Read more
-
Co-Founder, Co-CEO, President & Director
Mr. Chirag K. Patel
-
Co-Founder, Co-CEO, President & Director
Mr. Chirag K. Patel
-
Headquarters
Bridgewater, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Amneal Pharmaceuticals Inc Class A (AMRX)
What is the current share price of Amneal Pharmaceuticals Inc Class A (AMRX) Today?
The share price of Amneal Pharmaceuticals Inc Class A (AMRX) is $17.44 (NYSE) and $17.44 (NASDAQ) as of 04-Sep-2026 16:00 EDT. Amneal Pharmaceuticals Inc Class A (AMRX) has given a return of 60.48% in the last 3 years.
What is the current PB & PE ratio of Amneal Pharmaceuticals Inc Class A (AMRX)?
The P/E ratio of Amneal Pharmaceuticals Inc Class A (AMRX) is 36.33 times as on 04-Sep-2026, a 4 discount to its peers’ median range of 37.91 times.
The P/B ratio of Amneal Pharmaceuticals Inc Class A (AMRX) is 186.52 times as on 04-Sep-2026, a 2325 premium to its peers’ median range of 7.69 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
56.80 |
-57.81 |
2024 |
-20.99 |
-22.46 |
2023 |
-17.61 |
74.79 |
2022 |
-2.32 |
1.01 |
2021 |
67.35 |
1.99 |
What is the 52 Week High and Low of Amneal Pharmaceuticals Inc Class A (AMRX)?
The 52-week high and low of Amneal Pharmaceuticals Inc Class A (AMRX) are Rs 19.26 and Rs 11.71 as of 06-Sep-2026.
What is the market cap of Amneal Pharmaceuticals Inc Class A (AMRX)?
Amneal Pharmaceuticals Inc Class A (AMRX) has a market capitalisation of $ 6,074 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Amneal Pharmaceuticals Inc Class A (AMRX)?
Before investing in Amneal Pharmaceuticals Inc Class A (AMRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.